Status:
UNKNOWN
Galantamine Executive Function in Parkinson's Disease
Lead Sponsor:
Memorial Hospital of Rhode Island
Collaborating Sponsors:
Ortho-McNeil Neurologics, Inc.
Conditions:
Parkinson's Disease
Eligibility:
All Genders
60-85 years
Phase:
NA
Brief Summary
The aim of the study is to determine whether galantamine stabilizes or improves thinking abilities in individuals with Parkinson's disease. Individuals included in the study have minor complaints abou...
Detailed Description
While several cholinesterase inhibitors have effectiveness in Alzheimer's disease (AD), galantamine is unique since it has a dual mode of action: inhibition of acetylcholinesterase and modulation of n...
Eligibility Criteria
Inclusion
- Idiopathic Parkinson's Disease
Exclusion
- dementia, depression, cardiac disease, gastrointestinal disease
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2007
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00211588
Start Date
June 1 2004
End Date
May 1 2007
Last Update
May 7 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Hospital of RI
Pawtucket, Rhode Island, United States, 02860